Figure 2
From: Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients
The incidence (bars) and cumulative prevalence (lines) of pneumocystis infection at different time points post chemotherapy in HIV-uninfected non-Hodgkin lymphoma patients. (blue bar/line: rituximab group, red bar/line: control group) (X axis: weeks post chemotherapy; Y axis: case number). Most pneumocystis infections occurred within 20 weeks post rituximab treatment, while the peak incidence was at approximately 6 to 16 weeks post treatment.
